What is Histogen Inc. (HSTO)?

Histogen Inc. (HSTO) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of HSTO?

The current price of HSTO is $0.02. Prices are updated in real time on Stocks360.

What is HSTO's price-to-earnings (PE) ratio?

HSTO's trailing twelve-month PE ratio is -0.01, based on current price and earnings per share data available on Stocks360.

What is HSTO's market capitalization?

HSTO's market capitalization is $85,435.00, placing it in the small-cap tier.

Histogen Inc. (HSTO)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.02

Market Cap

$85.44K

PE (TTM)

-0.01

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.12

Day Range

$0.02 – $0.02

52-wk Range

$0.02 – $0.02

Avg Volume

N/A

Volume

0.00

Histogen Inc. (HSTO) is a publicly traded company in the Healthcare sector. Latest price: $0.02. Market cap $85.44K. Trailing PE -0.01. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Nov 9, 2023

EPS $-0.90 vs est. $-0.54

Missed by $0.36

Proprietary Signals

Signal snapshot temporarily unavailable.

About Histogen Inc.

Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.01×
P/S (TTM)	0.02×
P/B	0.00×
P/FCF (TTM)	-0.01×
EV / EBITDA	0.70×
EV / Sales	-1.96×
Earnings Yield	-16538.46%
Free Cash Flow Yield	-11586.59%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$7.39M
Net Income (TTM)	-$14.13M
Free Cash Flow (TTM)	-$9.90M
Net Debt	-$7.48M
Working Capital	$12.22M
Gross Margin	100.00%
Operating Margin	-282.38%
Net Margin	-281.80%
Return on Equity	-59.67%
Return on Invested Capital	-58.85%